Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer: Current status and future perspectives
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three experts provide their insights on unmet needs, emerging therapies, and the importance of biomarker testing in HER2-negative gastric cancer/gastroesophageal junction cancer.
The experts:
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Astellas Pharma Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/exp_opin_HER2_negative_gastric_or_GE_junction_cancer
Create your
podcast in
minutes
It is Free